Physician profile
Daniel W Coyne
NPI 1427074749
$163,182.96
in general payments reported to CMS, 2019-2025
14 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $14K · 2021: $18K · 2022: $21K · 2023: $7,079 · 2024: $8,755 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Travel and Lodging: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,500 · Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,465.64 |
| Travel and Lodging | $12,153.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,500.00 |
| Food and Beverage | $384.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $67,610.78 | 2019-2025 | Velphoro |
| Astrazeneca Pharmaceuticals Lp | $20,429.62 | 2019-2021 | |
| Glaxosmithkline, LLC. | $19,668.99 | 2020-2023 | |
| Fresenius Kabi USA, LLC | $18,796.77 | 2021-2025 | |
| Akebia Therapeutics INC | $16,854.59 | 2021-2024 | Vafseo, Auryxia |
| Rockwell Medical, INC. | $5,474.90 | 2019 | |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | $5,347.72 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $4,164.60 | 2021 | |
| Lilly USA, LLC | $3,675.00 | 2021-2022 | |
| Daiichi Sankyo INC. | $962.50 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $122.50 | 2020 | |
| Mallinckrodt Enterprises LLC | $74.99 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Coyne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.